Scientific deep-dive

GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning

Three of six GLP-1 labels warn about the contraceptive pill. Mounjaro and Zepbound set a four-week window after starting and after every dose increase, and Foundayo a 30-day one; the three semaglutide labels carry no such advisory. We read all six.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
9 min read·9 citations

Part of Safety and side effects, separated from the headlines

There is a labeled interaction between a GLP-1 medicine and the contraceptive pill, and it belongs to tirzepatide and orforglipron. Mounjaro and Zepbound both tell prescribers to steer a patient off a swallowed hormonal method, or to layer a barrier method on top of it, for four weeks from the first injection and again for four weeks after every increase in dose. Foundayo, the orforglipron tablet, gives the same instruction over 30-day windows. The three semaglutide labels (Ozempic, Wegovy and the oral tablets) carry no such advisory. We read all six on October 17, 2026 to confirm the difference.

What the tirzepatide labels tell prescribers

Section 8.3 of the Mounjaro label is where it lives. It says the drug can lower how well a swallowed hormonal contraceptive works, because the stomach is handing its contents on more slowly, and that the slowing is at its most pronounced after the very first dose before easing off. The instruction that follows is to move the patient off the swallowed method or add a barrier one, and to keep that in place for four weeks from the start of treatment and for four weeks following every step up in dose.[1] Zepbound carries the identical instruction with its clauses arranged differently, over the same two four-week spans.[2]

Both labels repeat it in three places: the Highlights box at the top, the drug interactions section, and the counseling text a prescriber is meant to deliver. That repetition is a fair signal of how much weight Eli Lilly puts on it. The version written for patients rather than clinicians is the plainest of the lot.

Birth control pills by mouth may not work as well while using MOUNJARO.
— Mounjaro medication guide, SPL version 40, effective August 27, 2026

Another sentence in the same section matters more than any of that. The labels state that hormonal contraception delivered by any route other than the mouth should not be affected.[1][2] The manufacturer draws that boundary itself, and it decides whether any of this applies to you.

Foundayo carries it too, without a study behind it

The orforglipron label repeats the instruction in its drug interactions section, its reproductive-potential section and its counseling text: move to a method that is not swallowed, or keep the pill and add a barrier, during the first 30 days of treatment and the 30 days following every dose increase. It also says hormonal contraception given by any other route should not be affected. The difference from tirzepatide is the evidence. By the label’s own account, nobody has run a clinical trial of what Foundayo does to oral contraceptive absorption. It rests the advisory on delayed stomach emptying alone.[9]

What the semaglutide labels do instead

None of the three carry a contraception advisory. Ozempic's label mentions an oral contraceptive exactly once, in a figure legend inside the clinical pharmacology section showing that ethinylestradiol and levonorgestrel exposure was measured and was not meaningfully changed.[3] Wegovy and the oral semaglutide label do not use the word at all; both list ethinyl estradiol and levonorgestrel among the drugs whose pharmacokinetics showed no clinically significant difference alongside semaglutide.[4][5]

Semaglutide also slows the stomach, and its labels also warn about oral medications generally, but the specific contraceptive advisory was not written for it. A pharmacology review of every approved GLP-1 agonist reached the same split independently: interactions driven by delayed gastric emptying are mostly clinically insignificant across the class, with tirzepatide and oral contraceptives named as one of the two exceptions worth monitoring.[6]

All six FDA labels tracked by this register, read from the DailyMed SPL on October 17, 2026.
LabelSPL version and effective dateContraception advisory?
Mounjaro (tirzepatide)v40, August 27, 2026Yes. Non-oral method, or a barrier added on top, held for four weeks from the first dose and four weeks past every step up
Zepbound (tirzepatide)v40, August 28, 2026Yes. The same two windows, the same wording, clauses reordered
Foundayo (orforglipron tablets)v10, July 29, 2026Yes. The same two options over 30-day windows; effect on the pill not tested in a trial
Ozempic (semaglutide injection)v20, June 1, 2026No. Oral contraceptive appears once, in a §12.3 figure legend
Wegovy (semaglutide)v19, June 18, 2026No. Ethinyl estradiol and levonorgestrel listed as showing no clinically significant difference
Rybelsus / Ozempic tablets (oral semaglutide)v14, January 30, 2026No. Same pharmacokinetic listing as Wegovy

The measurement underneath it

Both tirzepatide labels publish the study the advisory came from. A combined oral contraceptive was given with a single 5 mg dose of tirzepatide, and peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%. Total exposure across the day fell far less (by 20%, 21% and 23%), and the time to peak concentration was pushed back by two and a half to four and a half hours.[1][2]

Read that pattern and the advisory makes sense. The hormone still arrives; it arrives later and in a flatter curve, because the stomach handed it over more slowly. The same labels show the same effect on acetaminophen, and show it fading: after four to six weeks of continued dosing there was no meaningful impact on acetaminophen peak concentration at all.[1][2] That is why the window is four weeks rather than permanent, and why it re-opens at each step up. The slowed stomach behind it is the same mechanism that produces most of the drug's better-known effects, which we set out in what the tirzepatide record does and does not cover.

A reduction in peak concentration is not the same as a documented pregnancy. We could not find a trial that counted contraceptive failures on tirzepatide, and neither label reports one. What the labels do is describe a plausible mechanism precisely enough to act on. That is a reasonable basis for four weeks of a second method, and a poor basis for panic. Whether the flatter hormone curve also causes breakthrough spotting has not been studied; what is known about bleeding changes is in GLP-1 drugs and your period.

Which methods this touches

The label's phrase is oral hormonal contraceptives. Everything hinges on the route, not on the hormone. A 2026 review in a contraception journal reaches the practical version of the same conclusion: while someone is on one of these drugs, and particularly while gastrointestinal side effects are active, non-oral hormonal methods and long-acting reversible contraception are the more dependable choices.[8]

  • Affected, per the label: anything swallowed. Combined pills and progestin-only pills both go through the stomach, and the stomach is the whole mechanism.
  • Not affected, per the label: hormonal methods that skip the gut. The patch, the vaginal ring, the injection and the implant deliver through skin, mucosa or muscle, and a hormonal intrauterine device releases into the uterus. A copper IUD involves no hormone at all.
  • Barrier methods are unaffected by definition, which is why the label offers adding one as the alternative to switching.
  • We could not find emergency contraception addressed in any of the six labels. Oral emergency contraception is swallowed, so the same mechanism would apply in principle, but no label we read says so and we are not going to fill that gap ourselves. It is a question for a pharmacist or prescriber.

Counting the four weeks

The window is not a single month at the start of treatment. It runs four weeks from the first dose, and then four weeks again from each increase, and GLP-1 treatment is built around a ladder of increases spread over the first several months. On a stepped schedule the covered period recurs more often than most people expect from reading the advisory once. Foundayo works the same way, with 30 days in place of four weeks.[9]

We are not going to lay out a dose schedule here, and you should not calculate your own window from a general article. Your prescriber knows which step you are on and when the next one is planned. Ask them to mark the dates. Our companion piece on how long GLP-1 side effects last explains why the escalation phase, rather than the calendar month, is the coordinate that matters for most of these drugs' behavior.

The conversation that mostly is not happening

A 2026 study of 382 women aged 18 to 44 with type 2 diabetes, recruited across 38 Chicago health centers, found that half had been prescribed a GLP-1 receptor agonist. Among the 194 who had, 54.6% intended a future pregnancy and 40.7% were using hormonal contraception or an intrauterine device. Fewer than one in eight reported that pregnancy intention, contraception or preconception health had come up at their most recent visit.[7]

Women with limited health literacy were less likely still to have had the preconception conversation: 6.3% against 18.4%.[7] The gap is in the appointment, not in the label. If nobody has raised it with you, you are in common company. Raise it yourself, and do not take the silence as a sign it does not apply.

If you are pregnant, or think you might be, that is a same-week conversation with a clinician, not a page on a register. What the approved labels say about pregnancy and about stopping before a planned one is set out in GLP-1s, pregnancy and trying to conceive, and breastfeeding in GLP-1s while breastfeeding. The decision, though, belongs to someone who knows your history.

What to raise with a prescriber

  1. Which molecule am I actually on? The advisory is on the tirzepatide and orforglipron labels, not the semaglutide ones. If a telehealth service sold you "a GLP-1" without naming it, that is the first thing to establish.
  2. Am I inside a four-week window right now (from starting, or from the last increase), and when does the next increase fall?
  3. Is switching method or adding a barrier the better fit for me? The label offers both and does not rank them. Your prescriber can.
  4. Does this change if I have been vomiting or badly nauseated? A pill that does not stay down is a separate problem from a pill absorbed slowly, and it applies whichever molecule you are on.
  5. What is the plan if I want to try for a pregnancy? That question has a different answer for each drug, and the intervals are in pregnancy and trying to conceive.

If the service that prescribed your medication is hard to reach for a question like this, weigh that too. We record who dispenses for each seller and whether a named, state-licensed pharmacy is identifiable, on our pharmacy register.

Some services put this question in front of clinicians who handle hormones and contraception every day. Our board for the months after pregnancy starts from the same label limits and lists sellers that run a women’s health program. Allara Health lists OB-GYNs and endocrinologists among its clinicians, and Gaya Wellness is a virtual OB/GYN practice for women over 40 with weekly check-ins. Hormonally Balanced, a physician-led women’s hormone practice in Burlington, Massachusetts, prescribes weekly semaglutide or tirzepatide by telehealth in seven states, and Steady State Health runs its GLP-1 program inside a perimenopause and menopause plan in Oregon and Washington.

On reachability, Evernow offers 24/7 clinician messaging alongside its branded GLP-1s. The molecule question matters most where both drugs are on the menu: Kina and Trinity Meds each sell compounded semaglutide and tirzepatide, and 1st Optimal prescribes either one, as a daily tablet or a weekly shot, next to its women’s hormone plans.

Frequently Asked Questions

The three approved semaglutide labels do not say so. Ozempic, Wegovy and the oral tablets carry no contraception advisory, and all three report that ethinyl estradiol and levonorgestrel exposure was not meaningfully changed when given alongside semaglutide. That is what the labels say as of October 17, 2026. It is not a promise that nothing can go wrong, and severe vomiting is its own issue on any of these drugs.
No. Both tirzepatide labels and the Foundayo label state that hormonal contraception delivered by any route other than the mouth should not be affected. The mechanism is delayed stomach emptying, so a method that never passes through the stomach is outside it. That covers the patch, the ring, the injection, the implant and both hormonal and copper IUDs.
Both. The Mounjaro and Zepbound labels set the window at four weeks from the first dose and four weeks from every subsequent increase. Because these drugs are titrated upward in steps, the window comes back each time the dose goes up. The Foundayo label uses the same structure with 30-day windows. Ask your prescriber to put the dates against your own schedule rather than estimating from a general article.
That is a prescriber's call, not ours. The label offers two options and treats them as equivalent: move to a hormonal method that is not swallowed, or keep the pill and cover the window with a barrier method. Which suits you depends on things a register cannot see.
The molecule is the same, so the mechanism does not change. What changes is that a compounded preparation has no FDA-approved label of its own, so nobody has written this advisory down for you, and the dose steps may not match the approved ladder the four-week window was described against. Ask the prescriber directly.

References

  1. 1.Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, SPL version 40 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  2. 2.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, SPL version 40 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, SPL version 20 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  4. 4.Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information, SPL version 19 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. 5.Novo Nordisk Pharmaceutical Industries, LP RYBELSUS and OZEMPIC (oral semaglutide) tablets — prescribing information, SPL version 14 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Min JS, Jo SJ, Lee S, et al. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Drug Des Devel Ther. 2025. PMID: 40330819.
  7. 7.Bailey SC, Cameron NA, Batio S, et al. Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes J Womens Health (Larchmt). 2026. PMID: 42576647.
  8. 8.Dilbaz B, Ateş Ç The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives Eur J Contracept Reprod Health Care. 2026. PMID: 41860479.
  9. 9.Eli Lilly and Company FOUNDAYO (orforglipron) tablets, for oral use — prescribing information, SPL version 10 DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted

No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.

8 min read

Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?

GLP-1 users are diagnosed with gastroparesis more often, about 6.5 per 1,000 a year on semaglutide against 2.1 on another weight drug. What the Ozempic and Mounjaro labels added and when, whether it reverses, and where MDL 3094 stands.

11 min read

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.

6 min read

Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign

Stomach pain on Ozempic, Wegovy, Mounjaro or Zepbound is usually mild and comes with the dose increases. The labels describe the patterns that are not ordinary, and little of the usual advice has been tested.

8 min read

Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip

Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.

7 min read